BIOMAT Database Logo BIOMAT Database Logo

Mechanism of the haemodynamic interaction between atenolol, a cardioselective beta-adrenoreceptor-blocking agent, and chlorthalidone in hypertensive patients. 1979

M Velasco, and J Guevara, and J Morillo, and A Ramírez, and A Urbina-Quintana, and O Hernandez-Pieretti

UI MeSH Term Description Entries
D006973 Hypertension Persistently high systemic arterial BLOOD PRESSURE. Based on multiple readings (BLOOD PRESSURE DETERMINATION), hypertension is currently defined as when SYSTOLIC PRESSURE is consistently greater than 140 mm Hg or when DIASTOLIC PRESSURE is consistently 90 mm Hg or more. Blood Pressure, High,Blood Pressures, High,High Blood Pressure,High Blood Pressures
D008875 Middle Aged An adult aged 45 - 64 years. Middle Age
D010919 Placebos Any dummy medication or treatment. Although placebos originally were medicinal preparations having no specific pharmacological activity against a targeted condition, the concept has been extended to include treatments or procedures, especially those administered to control groups in clinical trials in order to provide baseline measurements for the experimental protocol. Sham Treatment
D011412 Propanolamines AMINO ALCOHOLS containing the propanolamine (NH2CH2CHOHCH2) group and its derivatives. Aminopropanols
D012039 Regional Blood Flow The flow of BLOOD through or around an organ or region of the body. Blood Flow, Regional,Blood Flows, Regional,Flow, Regional Blood,Flows, Regional Blood,Regional Blood Flows
D001794 Blood Pressure PRESSURE of the BLOOD on the ARTERIES and other BLOOD VESSELS. Systolic Pressure,Diastolic Pressure,Pulse Pressure,Pressure, Blood,Pressure, Diastolic,Pressure, Pulse,Pressure, Systolic,Pressures, Systolic
D002752 Chlorthalidone A benzenesulfonamide-phthalimidine that tautomerizes to a BENZOPHENONES form. It is considered a thiazide-like diuretic. Chlorphthalidolone,Phthalamudine,Chlortalidone,Hygroton,Oxodoline,Thalitone
D002986 Clinical Trials as Topic Works about pre-planned studies of the safety, efficacy, or optimum dosage schedule (if appropriate) of one or more diagnostic, therapeutic, or prophylactic drugs, devices, or techniques selected according to predetermined criteria of eligibility and observed for predefined evidence of favorable and unfavorable effects. This concept includes clinical trials conducted both in the U.S. and in other countries. Clinical Trial as Topic
D004311 Double-Blind Method A method of studying a drug or procedure in which both the subjects and investigators are kept unaware of who is actually getting which specific treatment. Double-Masked Study,Double-Blind Study,Double-Masked Method,Double Blind Method,Double Blind Study,Double Masked Method,Double Masked Study,Double-Blind Methods,Double-Blind Studies,Double-Masked Methods,Double-Masked Studies,Method, Double-Blind,Method, Double-Masked,Methods, Double-Blind,Methods, Double-Masked,Studies, Double-Blind,Studies, Double-Masked,Study, Double-Blind,Study, Double-Masked
D004347 Drug Interactions The action of a drug that may affect the activity, metabolism, or toxicity of another drug. Drug Interaction,Interaction, Drug,Interactions, Drug

Related Publications

M Velasco, and J Guevara, and J Morillo, and A Ramírez, and A Urbina-Quintana, and O Hernandez-Pieretti
Clinical electrophysiological effects of atenolol--a new cardioselective beta-blocking agent.
January 1978, British heart journal,
M Velasco, and J Guevara, and J Morillo, and A Ramírez, and A Urbina-Quintana, and O Hernandez-Pieretti
Haemodynamic effects of Trasicor, a new beta-adrenergic blocking agent, in hypertensive patients.
January 1969, Acta medica Scandinavica,
M Velasco, and J Guevara, and J Morillo, and A Ramírez, and A Urbina-Quintana, and O Hernandez-Pieretti
[Practolol, cardioselective adrenergic beta blocking agent].
October 1970, La Clinica terapeutica,
M Velasco, and J Guevara, and J Morillo, and A Ramírez, and A Urbina-Quintana, and O Hernandez-Pieretti
Digital arterial tone in hypertensive subjects treated with cardioselective and non-selective beta-adrenoreceptor blocking agents.
April 1981, Danish medical bulletin,
M Velasco, and J Guevara, and J Morillo, and A Ramírez, and A Urbina-Quintana, and O Hernandez-Pieretti
Glucose tolerance and insulin release in hypertensive patients treated with the cardioselective beta-receptor blocking agent metoprolol.
January 1977, Acta medica Scandinavica,
M Velasco, and J Guevara, and J Morillo, and A Ramírez, and A Urbina-Quintana, and O Hernandez-Pieretti
[Evaluation of cardiac performance in the hypertensive patient. Effect of a beta-blocking agent: atenolol].
October 1978, Archives des maladies du coeur et des vaisseaux,
M Velasco, and J Guevara, and J Morillo, and A Ramírez, and A Urbina-Quintana, and O Hernandez-Pieretti
A controlled study on the anti-hypertensive effect of a new beta-adrenoreceptor-blocking drug, metoprolol, in combination with chlorthalidone.
December 1976, Clinical science and molecular medicine. Supplement,
M Velasco, and J Guevara, and J Morillo, and A Ramírez, and A Urbina-Quintana, and O Hernandez-Pieretti
Comparison of the effectiveness of a beta blocker (atenolol) and a diuretic (chlorthalidone) in black hypertensive patients.
December 1984, Southern medical journal,
M Velasco, and J Guevara, and J Morillo, and A Ramírez, and A Urbina-Quintana, and O Hernandez-Pieretti
Pulmonary effects of acebutolol, a "cardioselective" beta adrenergic blocking agent.
January 1982, International journal of clinical pharmacology, therapy, and toxicology,
M Velasco, and J Guevara, and J Morillo, and A Ramírez, and A Urbina-Quintana, and O Hernandez-Pieretti
[Electrophysiological evaluation of a new cardioselective beta-blocking agent: metoprolol].
January 1977, Bollettino della Societa italiana di cardiologia,
Copied contents to your clipboard!